Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 951 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle treatment Clear all
Completed Phase 2 Interventional Results available

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

NCT02094716
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Foam 4%, Permethrin Foam 5%, Vehicle Foam
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Months and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Fremont, California • Los Angeles, California • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 3, 2026, 9:33 AM EDT
Active, not recruiting Phase 2 Interventional

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

NCT04114825
View directory record Official record
Conditions
Prostate Cancer Recurrent
Interventions
RV001V, Placebo
Biological · Other
Lead sponsor
RhoVac APS
Industry
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Clearwater, Florida • Towson, Maryland • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)

NCT00933543
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Visonac PDT (MAL PDT), Vehicle cream (placebo), PDT
Drug · Procedure
Lead sponsor
Photocure
Industry
Eligibility
9 Years to 35 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Naperville, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis

NCT01321359
View directory record Official record
Conditions
Recurrent Herpes Simplex Labialis
Interventions
Vehicle versus NB-001
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
907 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
35
States / cities
Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne

NCT02815280
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX-101, 4% minocycline foam, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Glendale, Arizona • Rogers, Arkansas • Oceanside, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Clinical Trial in Females for Female Pattern Hair Loss

NCT01226459
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5% Minoxidil Topical Foam, Vehicle Topical Foam
Drug
Lead sponsor
Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Wichita, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Study of ST-100 as Treatment for Dry Eye Disease

NCT05241470
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ST-100 Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Stuart Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis

NCT02595073
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DSXS, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 3, 2026, 9:33 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Proof of Concept Study of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation

NCT05790941
View directory record Official record
Conditions
Hypotrichosis
Interventions
Latanoprost and Minoxidil
Combination Product
Lead sponsor
Aneira Pharma, Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Indian Wells, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Cellular and Molecular Events During Treatment of Actinic Keratosis With Imiquimod 5% Cream

NCT00335179
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aldara (imiquimod 5% cream), Vehicle cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Sep 3, 2026, 9:33 AM EDT
Not listed Phase 1Phase 2 Interventional

Intranasal Neuropeptide Y in Clinical Trial in Level Two Trauma Patients for PTSD and Acute Stress Disorder

NCT04071600
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Stress Disorders, Traumatic, Acute
Interventions
Neuropeptide Y, Placebo
Drug · Other
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye

NCT01393132
View directory record Official record
Conditions
Dry Eye, Sjogren's Syndrome, Graft vs. Host Disease
Interventions
Thymosin Beta 4 eye drops, Vehicle Control
Drug
Lead sponsor
Michigan Cornea Consultants, PC
Other
Eligibility
18 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Sep 3, 2026, 9:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

NCT05891795
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clascoterone 1% Top Cream, Vehicle
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 3, 2026, 9:33 AM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma

NCT05852717
View directory record Official record
Conditions
Large Cell Lymphoma, Diffuse, Relapsed Cancer, Refractory Cancer
Interventions
AutoSCT OR CAR T-cell Therapy, GDP, Epcoritamab
Procedure · Drug
Lead sponsor
Dipenkumar Modi
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers

NCT01656889
View directory record Official record
Conditions
Venous Leg Ulcers
Interventions
HP-802-247, Vehicle
Biological
Lead sponsor
Healthpoint
Industry
Eligibility
18 Years and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
45
States / cities
Glendale, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

NCT00688519
View directory record Official record
Conditions
Psoriasis
Interventions
U0267, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 3, 2026, 9:33 AM EDT
Withdrawn Phase 2Phase 3 Interventional Accepts healthy volunteers

Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris

NCT03361345
View directory record Official record
Conditions
Postinflammatory Hyperpigmentation
Interventions
Tranexamic Acid, Vehicle
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 2 Interventional

Three-Arm Trial of Novel Treatment for Tinea Pedis

NCT03135912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride
Drug
Lead sponsor
South End Skin Care
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 2 Interventional Results available

AGN-199201 for the Treatment of Erythema With Rosacea

NCT01735201
View directory record Official record
Conditions
Rosacea, Erythema
Interventions
AGN-199201 Dose A, AGN-199201 Dose B, AGN-199201 Dose C, AGN-199201 Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 3, 2026, 9:33 AM EDT
Terminated Phase 3 Interventional Results available

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

NCT04931667
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Lorecivivint
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Tucson, Arizona • Winter Park, Florida • Oak Brook, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery

NCT01060072
View directory record Official record
Conditions
Inflammation, Pain
Interventions
Loteprednol etabonate, Vehicle of Loteprednol Etabonate
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 3, 2026, 9:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 3, 2026, 9:33 AM EDT
Terminated Phase 2 Interventional

FST-100 Ophthalmic Suspension in Acute Adenoviral Conjunctivitis

NCT00941486
View directory record Official record
Conditions
Acute Adenoviral Conjunctivitis
Interventions
FST-100 Ophthalmic Suspension, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
3 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
13
States / cities
Torrance, California • Colorado Springs, Colorado • Hamden, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Sep 3, 2026, 9:33 AM EDT